Oncology Institute (TOI) awards 31,124 RSUs to director Johnson
Rhea-AI Filing Summary
Johnson Karen Marie reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. granted director Karen Marie Johnson 31,124 restricted stock units (RSUs), each convertible into one share of common stock. The RSUs vest in full at the company’s 2027 annual meeting of stockholders, subject to her continued service, increasing her direct holdings to 319,410 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 31,124 shares
Net Buy
1 txn
Insider
Johnson Karen Marie
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 31,124 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 319,410 shares (Direct)
Footnotes (1)
- F1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.
Key Figures
RSU grant size: 31,124 shares
Holdings after grant: 319,410 shares
Grant price per share: $0.0000 per share
+1 more
4 metrics
RSU grant size
31,124 shares
Restricted stock units granted to director on 2026-07-27
Holdings after grant
319,410 shares
Director’s direct common stock holdings following the RSU award
Grant price per share
$0.0000 per share
Reported transaction price for the RSU award
Vesting event year
2027
RSUs vest in full on the date of the 2027 annual meeting of stockholders
Key Terms
restricted stock units (RSUs), settlement, vest, continued service
4 terms
restricted stock units (RSUs) financial
"Represents grant of restricted stock units (RSUs), each of which entitle"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
settlement financial
"entitle the Reporting Person to receive one share ... upon settlement."
Settlement is the process of completing a financial transaction, like buying or selling a stock, by transferring money and ownership between parties. It ensures that both the buyer gets the asset and the seller gets paid, making the deal official. Without settlement, the transaction wouldn't be finalized or legally recognized.
vest financial
"The RSUs vest in full on the date of the Issuer's 2027 annual"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
continued service financial
"subject to the Reporting Person's continued service with the Issuer"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity award did Oncology Institute (TOI) grant to Karen Marie Johnson?
Oncology Institute granted director Karen Marie Johnson 31,124 restricted stock units (RSUs). Each RSU entitles her to receive one share of common stock upon settlement, reflecting equity-based compensation rather than a cash purchase.
When do Karen Marie Johnson’s new RSUs at Oncology Institute (TOI) vest?
The 31,124 RSUs granted to Karen Marie Johnson vest in full on the date of Oncology Institute’s 2027 annual meeting of stockholders. Vesting is conditioned on her continued service with the company through that meeting date.
Was Karen Marie Johnson’s Oncology Institute (TOI) transaction under a Rule 10b5-1 plan?
The disclosure indicates the Rule 10b5-1 checkbox is not marked, and the transaction is described as a grant or award of RSUs. It is equity compensation, not an open-market trade executed under a trading plan.
What type of security did Oncology Institute (TOI) use for this director compensation?
Oncology Institute used restricted stock units (RSUs) for this director compensation. Each RSU represents a right to receive one share of common stock upon settlement, subject to vesting and continued service conditions.